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Background: Estimates of the cost of long-term compli-
cations of a primary deep vein thrombosis (DVT), includ-
ing the post-thrombotic syndrome (PTS) and recurrent
venous thromboembolism (VTE), may be relevant for
resource allocation decisions.
Objective: The objective of this study was to provide US
cost estimates of the long-term complications of a
primary DVT, which occurs in approximately 5% to 20%
(with adequate thromboprophylaxis) and 50% (in the
absence of thromboprophylaxis) of total hip replacement
surgeries (THRS).
Methods: A literature-based model was used to project
the excess long-term complication costs of DVT follow-
ing THRS. The model simulated the natural history of
DVT complications using published estimates of the inci-
dence and prognosis of PTS and recurrent VTE. Each
complication was assigned a cost obtained by multiply-
ing the amount of resources used in its management by
the unit price of these resources.
Results: The annual per-patient cost of each complication
was as follows: mild-to-moderate PTS, $839 in the ﬁrst
year and $341 in subsequent years; severe PTS, $3817 
in the ﬁrst year and $1677 in subsequent years; DVT,
$3798; and pulmonary embolism, $6604. The average
discounted lifetime cost of DVT complications was esti-
mated to be $3069 (95% interval $2091–$4279).
Conclusions: The long-term complications of a primary
DVT represent a signiﬁcant economic burden. Preventing
a DVT could arguably lead to substantial savings in long-
term DVT complications.
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ABSTRACT
Introduction
Deep vein thrombosis (DVT) is a major complica-
tion of total hip replacement surgery (THRS),
which occurs in 5% to 20% of patients receiving
adequate thromboprophylaxis and 50% in the
absence of DVT prevention [1,2]. In the short term,
DVT can result in morbidity and mortality from
pulmonary embolism (PE). The long-term clinical
course following DVT can be further complicated
by excess mortality, recurrent venous thromboem-
bolism (VTE), and post-thrombotic syndrome (PTS)
[3,4]. PTS is a constellation of signs and symptoms
that frequently follows a vascular thrombosis,
ranging from pain, skin pigmentation, and swelling
in the lower extremities to the formation of recur-
ring venous leg ulcers resulting in chronic pain,
decreased mobility, and ongoing medical resource
utilization [5–7]. The PTS results from the increased
venous pressure owing to residual obstruction or
valvular reﬂux as well as general damage to or
destruction of the venous valves and walls of the
deep veins and communicating veins of the leg fol-
lowing DVT and obliteration of the thrombosed
veins rather than recanalization [1,8]. Although the
clinical manifestations of PTS are well known, the
quality-of-life (QOL) and socioeconomic impacts of
PTS have not been extensively documented, except
for the most severe forms of the syndrome, such as
venous leg ulcer [7,8]. To the best of our knowl-
edge, only one study in Europe [9] and another
study in the United States [10] have attempted to
determine the costs associated with the entire range
of long-term complications of DVT. Costs-of-illness
estimates are important inputs for policy decisions.
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However, such estimates are lacking in the context
of the long-term complications of DVT. Our objec-
tive was to provide a baseline measure of the
resources used and costs to manage the long-term
complications of DVT. These estimates were
derived in the context of a DVT occurring after
THRS for several reasons. First, as opposed to idio-
pathic DVT or DVT resulting from the use of drug
therapy, such as oral contraceptive or hormone
replacement therapy, DVT-complicating surgeries
such as THRS are extremely common, if not
inevitable, without preventive measures [2]. Fortu-
nately, DVT following surgery can actually be pre-
vented with aggressive thromboprophylaxis using
oral anticoagulants and compression stockings,
unlike other idiopathic or drug-induced DVT.
Finally, to date, a large part of the literature on 
the economics of DVT prevention has focused on
orthopedic surgery and in particular THRS.
Accordingly, a baseline estimate of the costs associ-
ated with long-term complications of DVT in the
context of THRS should help decision makers
better appreciate the overall value of aggressive
thromboprophylaxis measures.
Materials and Methods
Model Overview
A literature-based Markov model using probabilis-
tic sensitivity analysis via Monte Carlo simulation
was developed to project the clinical, QOL, and
economic burden of long-term complications of a
primary DVT following THRS in the United States.
The target population for this analysis was com-
posed of two hypothetical cohorts of patients. Both
cohorts were similar in age at 72 years old and in
sex at 65% women to the population of all patients
undergoing THRS in the United States as reported
in the 1995–1996 Health Care Utilization Project
(HCUP, Agency for Healthcare Research and
Quality, Rockville, MD). However, one of the two
cohorts was representative of patients who would
have developed and survived a primary DVT fol-
lowing a THRS (i.e., the cases), while the other was
representative of patients not experiencing a DVT
following THRS (i.e., the controls). By comparing
the lifetime costs and survival of cases and controls,
the model allows the estimation of the long-term
economic cost and survival impact attributable to
the development of a primary DVT following
THRS.
The analysis was performed from the perspective
of payers responsible for the direct medical costs in
both the inpatient and the outpatient setting. Indi-
rect costs, such as time loss to seek care and pro-
ductivity losses, were therefore not included in this
analysis. We included time preference by discount-
ing future economic and health consequences at an
annual rate of 3%.
The Markov model depicts the natural history of
post-DVT complications (i.e., PTS, recurrent VTE,
and death) as an evolving sequence of 16 “health
states” deﬁned to capture important traits (i.e.,
QOL and cost) of these complications (Fig. 1). Of
these 16 health states, 13 were actually used in the
simulation and the additional 3 were included to
help frame the clinical problem at hand. Speciﬁcally,
following THRS, an individual can experience a
DVT and survive the short-term period following
this event, experience DVT but die from its com-
plications from PE or treatment-related complica-
tions, or experience no DVT and therefore survive.
Once patients have gone through these three states,
the simulation effectively begins with the survivors
in the two main groups: the “cases,” patients who
survived a primary DVT following surgery, and the
“controls,” patients who survived without experi-
encing a primary DVT following surgery. As time
passes, individuals who have survived a primary
DVT after surgery (i.e., the cases) can remain in 
this post-DVT state, develop signs and symptoms 
of mild-to-moderate PTS, signs and symptoms of
severe PTS, or die. Patients who did not experience
a primary DVT after surgery (i.e., the controls) are
also assumed to experience idiopathic PTS, albeit
less frequently. The model established a distinction
between the ﬁrst and subsequent years after the
development of PTS to allow for differences in diag-
nostic and treatment patterns and associated costs
that occur at different rates in the ﬁrst and subse-
quent years. Once patients entered in the PTS states,
they remained in these states until they died or the
end of the simulation at the age of 100 years.
Because of limited epidemiologic data, the model
further assumed no movements of patients between
the mild-to-moderate PTS and severe PTS states.
Finally, patients also incur costs as a result of VTE
events, which were accounted for as isolated clini-
cal events rather than as health states. VTE also
occurred relatively more frequently among patients
with a history of DVT.
The deﬁnition of PTS used in the model followed
the clinical-etiologic-anatomic distribution-patho-
physiologic (CEAP) dysfunction system [15]. As 
its name indicates, the clinical classiﬁcation of 
the CEAP is based on a combination of etiologic
classiﬁcation (congenital, primary, or secondary),
anatomic distribution (superﬁcial, deep, or perfo-
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rating, including subclassiﬁcations for each), and
pathophysiologic dysfunction (reﬂux, obstruction,
or both). Table 1 presents the six classes included
in the CEAP. In the model, mild-to-moderate PTS
and severe PTS refer to clinical classes 1–4 and 5–6,
respectively. All patients developing severe PTS 
for the ﬁrst time were classiﬁed as “severe, open
ulcer,” following the assumption that an ulcer must
be open before being healed. In addition, although
an ulcer may heal (clinical class 5), patients who
had developed an ulcer were assumed to remain in
the severe PTS health state, alternating between
healed and open ulcer status, for the rest of their
lives.
Data and Assumptions
Natural history and clinical outcomes. Data from
Prandoni et al. [16] were used to estimate the inci-
dence rate of PTS following a DVT (i.e., among
cases). This 8-year observational prospective study
followed 528 consecutive patients with a ﬁrst
episode of symptomatic, venographically conﬁrmed
DVT to monitor the development of complications
of a primary DVT, such as PTS, recurrent VTE, and
mortality. The rate of idiopathic PTS among con-
trols was assumed to be similar to that of the
general population and was taken from a popula-
tion-based study in the United States [17].
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Figure 1 Overview of the model.
Table 1 PTS by the CEAP classiﬁcation system
Clinical symptoms Class
No visible or palpable signs of venous disease 0
Telangiectases, reticular veins, malleolar ﬂare 1
Varicose veins 2
Edema without skin changes 3
Skin changes ascribed to venous disease (e.g., pigmentation,
venous eczema, lipodermatosclerosis) 4
Skin changes as described above with healed ulceration 5
Skin changes as described above with active ulceration 6
Note: In addition to the above classiﬁcation, the CEAP requires the catego-
rization of each limb as symptomatic or asymptomatic. Adapted from Bebbe
et al. [15].
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Patients that developed leg ulcers because of
venous insufﬁciency were considered to have severe
PTS. Accordingly, all patients in whom severe 
PTS developed for the ﬁrst time were considered 
by deﬁnition to have an open ulcer. Although 
ulcers can heal, the underlying condition remains,
as the damage to the venous system is serious 
and irreversible. Therefore, from the second year
onward, patients were assumed to remain in 
the severe PTS state, with alternating periods 
of time during which they would have open and
healed ulcers. Speciﬁcally, at any given time after the
ﬁrst year with severe PTS, 31.5% and 68.5% of
patients would have an open and a healed ulcer,
respectively.
In addition, patients in the model were at risk 
for recurrent VTE. Prandoni et al. [16] provides the
incidence rate of recurrent DVT and PE in cases. It
was assumed that 20.8% of recurrent VTEs would
be PEs [16]. Finally, patients who did not develop
a DVT following surgery were assumed to experi-
ence idiopathic DVT and PE at the incidence rates
observed in the general population (i.e., 160 DVT
per 100,000 and 70 PE per 100,000) [1].
Survival curves were constructed to model the
life expectancy of patients in both groups. Patients
who survive THRS surgery typically have a very
favorable life expectancy [20,21]. In contrast, there
is evidence that the long-term survival of patients
who have experienced a DVT is compromised
[3,9,16]. In the baseline model, survival curves for
the ﬁrst 15 years of the simulation were modeled
based on an observational study of long-term com-
plications and survival after acute DVT [9]. This
study found that the survival of patients who had
an acute DVT was shorter than for age- and sex-
matched controls that did not experience a DVT. To
complete survival curves up to the age of 100 years,
US life tables [22] were used, explicitly assuming
patients in both groups would experience the life
expectancy of the general population. In the sensi-
tivity analyses, a scenario in which no difference in
survival was assumed between cases and controls
was conducted. In this scenario, all patients had a
life expectancy identical to the age- and sex-
matched control group as reported in Bergqvist et
al. [9] for the ﬁrst 15 years, and, for subsequent
years, patient survival was based on the US life
tables provided by Anderson [22].
Health-related quality-of-life adjustments. Life
expectancy was adjusted for quality of life by using
health state utilities (Table 2). Utilities represent an
individual patient’s preferences for a given health
state and are scaled from 0 to 1. Quality-adjusted
life years (QALY) are calculated by multiplying the
time spent in a given health state by the utility value
of that state. For the health state associated with no
complications after DVT, weighted age- and sex-
speciﬁc utilities obtained using the Quality of Well-
Being Scale from a community sample of adults
were used [23]. QALY weights for mild-to-moder-
ate PTS and severe PTS were based on standard
gamble utilities obtained from healthy volunteers
[24]. Decrements in utility for recurrent VTE and
treatment complications were expressed in days lost
equivalent to the length of hospital stay [25].
Estimation of costs. The costs for diagnosis and
treatment of PTS and VTE were estimated in several
steps. First, patient care protocols were deﬁned by
the literature to speciﬁcally identify the key, direct
cost resource use items required for managing
patients with PTS. The cost was expressed in
US$2000 for each of these protocols and was then
determined. This was accomplished by ﬁrst esti-
mating the type and amount of resources that
would be used with each protocol. Resource use
items included physician/ nurse ofﬁce visits, diag-
nostic tests, medical supplies, medications, hospi-
talizations, and surgeries. The annual cost of these
complications was then obtained by multiplying the
amount of resource use by their unit costs. Appen-
dix A details the patient care protocols and associ-
ated costs for PTS.
Patient care protocol for mild-to-moderate PTS.
Limited information is available in the literature
Table 2 Utility weights
Variable Estimate Range tested Reference
Age- and sex-speciﬁc estimate
Women
65–74 0.71 0.10* [23]
75–84 0.67 0.11* [23]
85+ 0.67 0.10* [23]
Men
65–74 0.73 0.11* [23]
75–84 0.68 0.10* [23]
85+ 0.61 0.07* [23]
M/M PTS† 0.98 0.04* [23]
Severe PTS† 0.93 0.07* [24]
DVT‡ 5.9 days 2.65–8.85 [25]
PE‡ 7.1 days 3.55–10.65 [25]
Note:Adapted from Gould et al. [25].
*Standard deviation around the mean used to construct log normal distribu-
tion function for probabilistic sensitivity analysis according to Doubilet et al.
[13].
†Utilities are expressed as a ratio from age- and sex-speciﬁc estimate.
‡Decrements in utility expressed as days lost equivalent to the duration of hos-
pitalization.
Abbreviation: M/M, mild-to-moderate.
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regarding standard care protocols for patients with
mild-to-moderate PTS. While several surgical pro-
cedures are available, conservative management is
largely preferable [8]. Diagnosis of mild-to-moder-
ate PTS includes a clinical evaluation by a physician
and ultrasonography of the vascular system in legs
[8].The cornerstone of therapy is indeﬁnite use of
Grade 2 elastic compression stockings to reduce
venous hypertension, improve tissue microcircula-
tion, and prevent progression to severe PTS and
open venous ulcers [6]. Some patients may beneﬁt
from surgical intervention early on to prevent pro-
gression to severe PTS [26]. While perceptions of
managing PTS are slowly changing, the American
Venous Forum recognizes that for many years
venous disease has been considered the “stepchild”
of vascular surgery, resulting in less than optimal
care for many patients, such as clinic care by
medical students for open ulcers [27]. For primary
care practitioners, training in the diagnosis and
management of venous disease is lacking and diag-
nosis/intervention may not occur until patients
progress beyond the mild/moderate stage, at which
point they are then referred to a vascular surgeon
[27]. Therefore, because the symptoms of PTS often
go unrecognized or are ignored for months or even
years, we assumed that only about 50% of mild-to-
moderate PTS patients would actually be identiﬁed
and receive care for PTS. In sensitivity analyses, this
proportion ranged from 25% to 75%. We also used
the clinical expertise and experience of two of our
authors, J.A.C. and A.T.C., to supplement the gaps
in the literature such as selection of speciﬁc proce-
dure codes for applying costs and speciﬁc frequency
of some resources used.
For the initial work-up of mild-to-moderate 
PTS, 50% of patients would receive a level 5 (CPT
99215) physician ofﬁce visit and a duplex ultra-
sound scan of the venous anatomy. A small pro-
portion of patients equaling 7.5% without palpable
pedal pulses would also receive an arterial Doppler
as part of the differential diagnostic evaluation.
Once diagnosis was conﬁrmed, 50% of patients
would receive Grade 2 elastic compression stock-
ings, with 30 to 40 mmHg pressure at the ankle, as
ﬁrst-line management. During follow-up care in the
ﬁrst year, 50% of the patients would receive
approximately 4 level 3 (CPT 99213) follow-up
ofﬁce visits. Some patients would also receive level
1 nurse visits (CPT 99211) for education or skin
care. In addition, 20% of patients would receive
vein legation and stripping.
In subsequent years, routine follow-up care con-
sisted of regular physician ofﬁce visits and appro-
priate nurse visits, periodic reevaluation with
duplex ultrasound and arterial Doppler, and use of
Grade 2 compression stockings.
Patient care protocol for severe PTS. For severe
PTS, the comprehensive patient care protocol to
achieve healing of an open ulcer was based on pub-
lished guidelines for the management of venous leg
ulcers, supplemented with expert panel opinion for
utilization frequencies of various resources and
selection of procedure codes for costing purposes
[6,28]. All patients with severe PTS were assumed
to seek and receive care.
Components of care included physician ofﬁce
visits, nurse visits for wound care, compression ban-
dages (Unna’s paste boot or long- or short- com-
pression bandages), medications such as antibiotics,
home health care, hospitalization, outpatient 
surgical debridement of wounds, and skin grafting
[28]. For costing severe, open-ulcer PTS, a study 
by Marston et al. [29] was used. This study outlined
the care and associated costs required to heal 
an open ulcer based on its size. Of those patients
with open ulcers, 36% had an ulcer size of < 5cm2,
37% were size 5 to 20cm2, and 27% were size 
> 20cm2.
For patients with open ulcers, 75% received a
prescription for a ﬂuoroquinolone to manage infec-
tion on an outpatient basis as part of wound care.
Hospitalization for severe cellulitis and/or uncon-
trolled edema was required in approximately 7% of
severe, open-ulcer PTS patients [29]. In some rare
instances, patients were assumed to undergo ampu-
tation (0.4%), skin graft (2%), and debridement
(2%). After ulcer healing in the ﬁrst year, 10% of
severe PTS patients would receive vein legation and
stripping procedures and about 5% would receive
subcutaneous endoscopic perforator surgery
(SEPS).
Follow-up care for patients with healed ulcers
included 4 level 4 (CPT 99214) physician ofﬁce
visits per year. Duplex ultrasound scan was repeated
annually for all severe PTS patients and arterial
Doppler was used for follow-up care in 20% of
patients. All patients received Grade 2 elastic com-
pression stockings as the primary maintenance
measure after the ulcer healed.
Patient care protocol for VTE. Acute inpatient care
costs for recurrent VTE (DVT and PE) were based
on the average Medicare reimbursement for DRG
128 and 78, respectively. Follow-up outpatient care
included oral anticoagulation therapy for three
months [2,30] with warfarin (Dupont Pharmaceu-
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ticals, Wilmington, DE), using an average of 6 mg
per day to maintain the international normalized
ratio between 2 and 3, and an average of 9.25 pro-
thrombin time laboratory tests and two outpatient
follow-up visits.
Costing of patient care protocols. For inpatient
care, costs consisted of the average Medicare DRG
payment [31] plus the physician fees for the number
of days of inpatient follow-up care based on the
mean length of stay published with the DRG. Physi-
cian fees were based on designated CPT-4 codes.
Medicare reimbursements for physician fees were
gathered from Medicode’s National Fee Analyzer
[32].
For all outpatient care, such as vascular labora-
tory testing, ofﬁce visits, and minor surgeries, costs
consisted of the Medicare reimbursement rates for
physician or laboratory fees (based on CPT-4 codes)
plus the outpatient facility fee for that procedure.
Outpatient facility fees were gathered from the
Federal Register using Medicare Ambulatory
Payment Classiﬁcation (APC) codes [33]. Home
healthcare equipment costs were from the Centers
for Medicare and Medicaid Service’s (formerly
Health Care Financing Administration) Durable
Medical Equipment, Prosthetics/Orthotics, and
Supplies (DMEPOS) Fee Schedule [34]. Jobst 
Compression stocking costs were estimated using
retail prices. Drug costs were estimated using
average wholesale prices (AWP) from the RedBook
[35].
For severe PTS with open ulcers, a literature-
based estimate of the comprehensive cost to heal
ulcers was used [29]. The average cost of out-
patient care to heal an open ulcer (adjusted to
US$2000 prices) was $1372 for an ulcer size of 
<5cm2, $2045 for a size of 5 to 20cm2, and $5567
for a size of >20cm2 [29]. This study included
Medicare reimbursement levels of physician fees 
for evaluation and nonsurgical procedures; blood,
vascular, and other labs; and home health 
care. Hospital costs were used to estimate costs 
of wound dressing materials. No surgery was 
performed until ulcers healed. The hospital cost
component of inpatient SEPS was also based on the
literature [36].
Analyses
The model projects the cumulative incidence of PTS
and VTE, the average number of years of life spent
in the various health states, the life expectancy and
the quality-adjusted life expectancy of the patients
in the case and control groups. The annual costs
associated with each health state were estimated
based on the treatment protocols. These cost esti-
mates were subsequently used to project the lifetime
costs of cases and controls and the subset of patients
who developed PTS.
All analyses were performed using probabilistic
sensitivity analysis via Monte Carlo simulation 
to account for parameter uncertainty [13,37]. This
method generated 5000 runs or trials of the 
model using a different set of values for the model
parameters selected from the assumed distribution
of the parameters for each run. All variables in the
model were included in the Monte Carlo simula-
tion, with the exception of mean age of surgery 
and discount rate, which remained held at their
baseline values, as recommended by Briggs [38]. 
In general, the exact distribution of the value taken
by the parameter was unavailable. In these cases,
triangular distributions were used. In triangular 
distributions, the likeliest value, that is, the baseline
value, falls between the minimum and maximum
values, assumed to be ± 50% from baseline,
forming a triangular-shaped distribution, which
shows that values near the minimum and maximum
are less likely to occur than those near the likeliest
value [39,40]. However, in a few instances with 
sex-speciﬁc utility and utility for time spent with
PTS, log normal distributions were used, following
the transformation proposed by Doubilet et al. 
[13]. The results of the 5000 simulations were 
then analyzed to determine mean and uncertainty 
intervals by taking the 2.5 and 97.5 percentile
values to represent endpoints (for a 95% interval)
for the outcomes of the model. Following Briggs
[38], we use the term “uncertainty interval” as a
generic term rather than employing the frequently
used “conﬁdence interval” or the Bayesian equiva-
lent “credible interval.” We conducted additional
univariate and multivariate sensitivity analyses 
to further 1) determine the robustness of the 
results and conclusions; 2) identify the parameters
that contributed the most to the results; and 3) 
identify important model uncertainties. This was
accomplished by testing the impact on results 
of adding or subtracting 50% from the baseline 
estimate of key parameters. Finally, the model 
was run using alternative discount rates (0% and
5%).
Finally, a separate scenario analysis was con-
ducted to test the impact of setting survival for all
cases equal to that of controls, as opposed to assum-
ing that cases have a shorter life expectancy than
controls.
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Results
Projected Incidence of Long-term Complications
The cumulative proportion of patients who sur-
vived an initial acute, postsurgery DVT who devel-
oped mild-to-moderate PTS was 21.47% (95% UI
13.08%, 29.83%) compared to 1.34% (95% UI
0.82%, 1.85%) in the control group. The cumula-
tive proportions of patients who survived an initial
acute, postsurgery DVT who developed severe PTS,
recurrent DVTs and PE were 8.11% (95% UI
5.04%, 11.22%), 24.38% (95% UI 15.17%,
34.20%), and 6.52% (95% UI 3.54%, 10.42%),
respectively. Corresponding ﬁgures for the control
group were 0.39% (95% UI 0.24%, 0.55%),
2.36% (95% UI 1.34%, 3.58%), and 1.00% (95%
UI 0.49%, 1.68%), respectively. Therefore, the
excess cumulative proportion for mild-to-moderate
PTS was 20.13% (95% UI 11.66%, 28.55%). Sim-
ilarly, the excess cumulative proportions of cases
developing severe PTS, DVTs, and PEs were esti-
mated at 7.72% (95% UI 4.63%, 10.83%),
22.02% (95% UI 12.69%, 31.88%), and 5.52%
(95% UI 2.44%, 9.45%), respectively.
Life Expectancy and Quality-adjusted 
Life Expectancy
On average, cases and controls were projected to
live for 11.21 years (95% UI 8.51, 14.93) and 14.55
years (95% UI 12.21, 17.72), respectively. There-
fore, the net long-term life-expectancy reduction
associated with developing a primary DVT was esti-
mated to be 3.34 years (95% UI 0.99, 7.59). The
model also projected differences in the amount of
time cases and controls spent with mild-to-
moderate PTS (2.44 vs. 0.18 years), severe PTS
(0.91 vs. 0.05 years), and without PTS (7.86 vs.
14.32 years). After adjustment for quality of life,
the model projected that cases lose about 2.31
(95% UI 0.54, 5.18) QALYs compared to controls.
Annual Cost of PTS and VTE
Based on the treatment protocols (Appendix A), the
annual costs of mild-to-moderate PTS during the
ﬁrst year of diagnosis and subsequent years were
$839 and $341, respectively (Table 3). The reduc-
tion in costs from the ﬁrst year to subsequent ones
was primarily attributable to a reduction in surgery-
related costs. By deﬁnition, all severe PTS patients
have open ulcers during the ﬁrst year and incur the
highest level of resource use and cost, amounting to
$3817 per patient. After the initial year, severe PTS
can take the form of either open or healed ulcers.
For patients with open ulcers, direct medical costs
were estimated to be $3295 per year. For healed
ulcers, annual costs were estimated to be $933 per
year, 76% lower than the cost for a ﬁrst-year open
ulcer. A weighted average of the annual costs of
open ulcer ($3395 in 31.5% of patients) and healed
ulcer ($933 in 68.5% of patients) was used as the
estimated cost of severe PTS, in the second year and
beyond, totaling $1677. The annual cost of diag-
nosis and treatment of DVT and PE events occur-
ring in the long term were estimated at $3798 and
$6404, respectively.
Lifetime Costs of Long-term DVT Complications
The model projected that cases would experience a
discounted remaining lifetime cost of $3311 (95%
UI $2312, $4539), an excess of $3069 (95% UI
$2091, $4279) compared to controls (Table 4).
Approximately half (55%) of the total excess costs
were incurred within the ﬁrst ﬁve years of the sim-
ulation (Fig. 2). After 15 years, the total discounted
excess lifetime cost was $2814. Sixty-three percent
Table 3 Annual cost of diagnosis and treatment of PTS by year and severity
M/M PTS Severe PTS
Year 1 Year 2+ Year 2+
Year 1 Year 2+ (open ulcer) (open ulcer) (healed ulcer)
Ofﬁce visits $161 $107 —* —* $291
Vascular lab tests $185 $104 —* —* $381
Medical supplies $130 $130 $202 $202 $260
Medications — — $66 $66 —
Vein ligation and stripping $363 — $182 — —
SEPS procedure — — $103 — —
Comprehensive ulcer treatment — — $2712 $2712 —
Other hospitalizations/procedures — — $552 $314 —
Total $839 $341 $3817 $3295 $933
*The costs of ofﬁce visits and vascular lab tests are included in the comprehensive ulcer treatment.
Abbreviation: M/M, mild-to-moderate.
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(95% UI 46%, 79%) of the discounted excess life-
time cost was attributable to PTS-related costs as
opposed to VTE-related costs. Approximately two-
thirds (64%) of the excess PTS costs were attri-
butable to severe PTS and one-third to
mild-to-moderate PTS. Over two-thirds (70%) of
the excess VTE costs was due to DVT as opposed
to PE.
Lifetime Costs of PTS
Among cases and controls, patients who developed
PTS were projected to incur $7,053 (95% UI
$4,665, $10,158) and $7,072 (95% UI $4,683,
$9,890) in PTS-related discounted cost over the
remainder of their lives, respectively.
Univariate Sensitivity Analyses
As Table 5 indicates, the net excess cost associated
with the long-term complications of a surgery-
related DVT is most inﬂuenced by the incidence of
severe PTS, recurrent VTE, and the mortality rate
among cases. Changes in the cost of managing
patients with PTS and recurrent VTE are also asso-
ciated with important changes in the net excess cost.
All other variables appear to have signiﬁcantly less
inﬂuence. When the several critical parameters were
simultaneously varied by ± 50%, the estimate of
discounted lifetime excess cost typically ranged
between approximately $1500 and approximately
$4500. Finally, in an analysis of extremes, all para-
meters were varied simultaneously by ± 50% to esti-
mate the lowest and the highest estimates of costs.
Based on these analyses, the estimate of discounted
lifetime excess cost ranged from an absolute
minimum of $449 to an absolute maximum of
$9554.
Scenario Analysis
When long-term survival for cases was set equal to
the survival of controls, the difference in QALY
Table 4 Discounted lifetime cost of diagnosis and treatment of long-term DVT complications
Cases Controls Difference
Mean 95% UI Mean 95% UI Mean 95% UI
Mild-to-moderate PTS $751 $330–$1351 $51 $23–$90 $700 $295–$1278
Severe PTS $1320 $720–$2116 $71 $40–$111 $1249 $658–$2023
DVT $857 $441–$1408 $70 $34–$118 $787 $391–$1319
PE $383 $173–$694 $50 $21–$94 $333 $135–$636
Total $3311 $2312–$4539 $242 $166–$334 $3069 $2091–$4279
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Figure 2 Discounted lifetime cost of long-term DVT complications over time: cases, controls, and net excess cost.
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between the two groups was reduced from 2.31 to
0.09 (95% UI 0.02, 0.26), but the cost difference
increased from $3069 to $3441 (95% UI $2372,
$4678). This is not surprising because as patients
with a history of DVT live longer, they should have
a longer exposure to the cost of DVT complications.
Discussion
Our model projects that the discounted excess life-
time costs of managing the long-term complications
of DVT after THRS can be substantial: $3069
(95% UI $2091, $4279; range $449–$9554). The
model also estimates that patients who develop PTS
will incur close to $7000 in discounted PTS-related
costs over the rest of their lives. Finally, surgery-
related DVTs are projected to continue to negatively
impact a patient’s quality-adjusted life expectancy
over the long term. For instance, we found that the
net impact of developing a primary DVT was esti-
mated to be a reduction in life expectancy of 3.34
years and a reduction in quality-adjusted life
expectancy of 2.31 QALYs.
Most payers share the heavy burden imposed by
the long-term complications of DVT. However,
because most patients developing DVT tend to be
of older age, and this is even more so the case for
patients developing DVT after THRS, which is typ-
ically performed in the eighth decade of life, the cost
of long-term DVT complications falls more heavily
on the Medicare program and other public payers
for older patients. In some cases, one can speculate
that the entire lifetime cost of DVT complications
will have to be carried by these public payers and
the patients themselves and their families. Ulti-
mately, however, society as a whole is responsible
for covering the expenditures related to these com-
plications, either via social contributions or via
insurance premiums.
In their Swedish study, Bergqvist et al. [9] found
that the total additional health care cost of treating
PTS was approximately $4285 over 15 years, based
on a 1990 dollar value. In our study, these costs
were lower: approximately $2814 after 15 years
and $3069 over the patients’ remaining lifetimes.
Bergqvist et al. also found that the 15-year costs of
long-term complications represent approximately
75% of the cost of a primary DVT. In our study,
similar ﬁndings were found: long-term complica-
tions represent 74% after 15 years and 81% in a
lifetime of the cost of a primary DVT. Finally,
among patients with a history of primary DVT,
Table 5 Sensitivity analyses
Parameters at 50%
Parameters Below baseline Above baseline
Univariate sensitivity analyses
Proportion of
Cases developing mild-to-moderate PTS $2673 $3419
Cases developing severe PTS $2394 $3699
Cases developing recurrent VTE $2446 $3647
Recurrent VTE that are PEs in cases $2971 $3121
Controls developing mild-to-moderate PTS $3071 $3021
Controls developing severe PTS $3082 $3011
Controls developing recurrent VTE $3088 $3005
Recurrent VTE that are PEs in controls $3053 $3039
Annual cost of
Mild-to-moderate PTS (Year 1) $2967 $3125
Mild-to-moderate PTS (Year 2+) $2777 $3315
Severe PTS (open ulcer) (Year 1) $2913 $3179
Severe PTS (open ulcer) (Year 2+) $2747 $3346
Severe PTS (healed ulcer) (Year 2+) $2862 $3231
Proportion of severe PTS that are open ulcers (Year 2+) $2832 $3261
Cost of a DVT episode $2654 $3438
Mortality rate in
Cases $3725 $2641
Controls $2988 $3083
Discount rate $3620 $2760
(rate at 0%) (rate at 5%)
Multivariate sensitivity analyses
Proportion of cases developing
PTS $2021 $4072
PTS or recurrent VTE $1421 $4672
Annual cost of PTS $2082 $4011
Cost of an episode of a DVT or a PE $2488 $3605
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more than one-third of the treatment cost was
attributable to recurrent DVT in Bergqvist et al.
versus 37% in the present study. In contrast,
approximately 75% of the total costs were incurred
within the ﬁrst 5 years in the Bergqvist et al. study,
whereas we found that only 55% of these costs
were incurred within this very short time frame.
Thus, despite the use of signiﬁcantly different
methods, our estimate of the lifetime costs of late
complications of DVT, albeit lower in absolute
value, appear to be consistent with that reported for
Sweden by Bergqvist et al. [9]. It is interesting to
note that both estimates are higher than the one
used by Gould et al. [25] in an analysis of the cost-
effectiveness of DVT treatments. In the latter study,
the lifetime cost of late complications of DVT was
approximately $2350 and was obtained by a crude
extrapolation of the Swedish data to the US setting.
In an attempt to generalize the validity of our
results, all analyses were performed using proba-
bilistic sensitivity analysis via Monte Carlo simula-
tion. This resulted in estimates of long-term excess
cost of DVT with a 95% uncertainty interval of
$2091 to $4279. Although one could argue that this
interval is relatively broad, it does provide some
useful information regarding the cost of long-term
complications of DVT.
There is no systematic data collection source in
this country that allows comprehensive, nationally
representative PTS medical cost information to be
obtained. In our study, we employed a method com-
monly used to determine costs [41,42]. Speciﬁcally,
we developed a model based on protocols for
patient care based on a review of the clinical liter-
ature and current clinical practice regarding appro-
priate treatment and expected outcomes and cost
for patients with PTS. Our cost estimates are
intended to reﬂect resource utilization associated
with good clinical practice and therefore do not nec-
essarily represent the amounts that would actually
be incurred by any particular patient, provider, or
third-party payer. Our cost estimates may be dif-
ferent had we employed alternative assumptions
regarding patient management, prices, incidence
rate, and prognosis.
We took great care in selecting assumptions for
highly sensitive variables. For instance, we conser-
vatively assumed that no new case of PTS would
occur beyond ﬁve years and adjusted our estimates
of the long-term cost of DVT by accounting for the
cost that patients would have experienced in the
absence of a DVT. Our assumption about the inci-
dence of PTS was based on a recent prospective epi-
demiologic study [16] in which patients were
aggressively managed to prevent the onset of PTS
and recurrent VTEs. Our selection of this study 
is consistent with previous economic research in
which this study was also used [25,43]. The cumu-
lative incidence rate of PTS reported in this popu-
lation was close to 30%, a conservative ﬁgure
compared to the pooled weighted average of 50%
(range 21–87%) based on 19 epidemiologic reports
[8]. Yet, some recent US studies seem to indicate
that the rate of PTS and long-term complications
after DVT, in particular among patients undergoing
THRS, is lower than assumed in the present analy-
sis. For instance, in a large retrospective epidemio-
logic study of Olmsted County, Minnesota,
patients, Heit et al. [17] found that the cumulative
incidence rate of venous stasis syndrome following
a DVT was only 16.3% at 5 years but it was 24.1%
after 20 years. More surprising, Ginsberg et al. [44]
found that the rate of PTS following an orthopedic
surgery-related DVT event was low (4.0–6.1%) and
comparable to similar percentage of patients who
did not develop a DVT following surgery (4.3%).
As discussed by Ginsberg et al. [44], the likely
explanation for these lower rates may be due to the
increasingly widespread universal DVT prophy-
laxis, which reduces the incidence of VTE and the
subsequent risk of associated long-term complica-
tions. One way to reconcile our results with the
recent US epidemiologic data would be to consider
that the projected cost of PTS reported here are rep-
resentative of the costs incurred when aggressive
DVT prophylaxis is not adopted. We have also
assumed that all cases of severe PTS reported by
Prandoni et al. [16] were venous ulcers. This
assumption may overestimate the actual rate of
ulcers found in this study, but is nevertheless con-
sistent with the range of rates reported in the liter-
ature. In addition, it is possible that the cost of
managing patients with severe PTS, but no active or
healed ulcer, would nevertheless require the level of
attention and care administered to manage ulcers
due to the severity and chronic nature of their con-
dition. To the extent that this is true, our estimate
probably provides an adequate estimate of the life-
time cost of long-term DVT complications.
Finally, in the main analysis, survival for cases
was shorter than for controls. This assumption 
was based on epidemiologic observations [3,9].
However, because patients who survive THRS
surgery typically have a very favorable life
expectancy, it is possible that cases could in fact
enjoy a survival similar to controls. Therefore, a
scenario was conducted in which cases and controls
had identical survival. This analysis showed that
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difference in QALY between the two groups
decreased from 2.31 (95% UI 0.54, 5.18) in the
baseline analysis to 0.09 (95% UI 0.02, 0.26), but
the cost difference increased from $3069 to $3441
(95% UI $2362, $4678). This ﬁnding suggests that
our cost estimate in the baseline may actually be
somewhat conservative. On the other hand, assum-
ing that survival between the cases and control is
identical, our estimate of QALY loss should be con-
sidered an overestimate.
The annual or per-case costs of long-term com-
plications of DVT that served as intermediate inputs
in the projection of lifetime costs were derived using
the protocols described above. A comparison of
these ﬁgures with other published analyses suggests
that our costing method is reasonable. For instance,
our costs of DVT ($3798) and PE ($6404) are 
consistent with estimates from the literature
[25,41–43,45]. Our estimate of the cost of treat-
ment of venous ulcers is also consistent with ﬁgures
reported in the literature. For instance, Olin et al.
[46] recently reported an average cost of treatment
of venous ulcer to be $9685 per patient per year.
The authors pointed out that their study might
underestimate true cost to the extent that it did not
include the cost of frequent recurrences [47–49].
Our cost estimates are likely underestimated to the
extent that indirect costs, such as productivity losses
and time spent seeking care, were not included.
The present estimates of the costs of long-term
complications of DVT were derived in the context
of THRS. However, these estimates can readily be
used in the context of DVT resulting from other
causes such as other surgeries, drug-induced DVT,
or idiopathic DVT, provided that the incidence of
long-term complications and prognosis, including
survival, do not differ signiﬁcantly from our
assumptions. The broad applicability of these esti-
mates is due in part to the reliance on epidemiologic
data representative of DVT following a wide range
of etiologies.
Despite its limitations, we believe that our study
provides a useful estimate for the cost of long-term
complications of DVT in the United States. It sug-
gests that DVTs result in a signiﬁcant long-term eco-
nomic burden for patients. Fortunately, the ability
to sharply decrease these high costs currently exists.
Although it is unclear that treatment of the initial
DVT with anticoagulant therapy or thrombolysis
reliably prevents PTS, primary DVT prevention
with compression stockings and pharmacotherapy
is likely more effective [6]. The American Heart
Association [30] states that the most effective way
to reduce the morbidity from PTS is to institute a
comprehensive institutional policy of primary pro-
phylaxis in patients at risk for VTE. Our cost esti-
mates suggest that adherence to primary prevention
measures could signiﬁcantly reduce health-care
costs. For instance, should the rate of DVT occur-
ring in 5% to 20% of 160,000 THRS performed in
the United States [50] be reduced by half, savings
of approximately $12 million to $50 million could
be achieved.
We conclude that our results provide yet another
justiﬁcation for the routine use of measures
designed to prevent VTE and its long-term com-
plications. At the same time, we recommend 
additional research to determine via prospective or
cross-sectional primary data collection the inci-
dence, quality-of-life, and economic impact of the
long-term effects of a venous thromboembolic
event, months and years after the initial event.
We thank Aventis Pharmaceuticals, Bridgewater, NJ, for
ﬁnancial support of this research.
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Appendix A
Table A1 Direct medical cost of mild-to-moderate PTS (Year 1)
Resource use items Probability (%) Number of units Cost per unit Annual total cost
Ofﬁce visits $160.91
Initial work-up physician visits 
(CPT 99215) 50.00 1.00 $108.74 $54.37
Follow-up physician visits 
(CPT 99213) 50.00 4.00 $47.23 $94.46 
Follow-up wound care clinic 
visits/nurse visits (CPT 99211) for 
patients with moderate PTS only 20.00 3.00 $20.14 $12.08
Vascular lab tests $185.08
Duplex ultrasound scan: physician
fee (CPT 93970 @ $205.4) plus 
facility fee (APC 0267 @ $131.88) 50.00 1.00 $337.28 $168.64
Arterial Doppler: physician fee 
(CPT 93923 @ $119.36) plus 
facility fee (APC 0096 @ $99.88) 7.50 1.00 $219.24 $16.44
Medical supplies $130.00
Grade 2 elastic compression 
stockings (knee-high 30–40
mmHg from Jobst), two pairs 
every 6 months 50.00 4.00 $65.00 $130.00
Vein ligation and stripping $363.46
Inpatient: hospital fee (DRG 119 
@ $5041.77) plus physician 
fees (CPT 37730 @ $519.55) 
and one physician visit per day 
for 4.9 days for subsequent 
inpatient management 
(CPT 99231 @ $35.88) 1.50 1.00 $5737.13 $86.06
Outpatient: physician fee 
(CPT 37730 @ $519.55) 
plus facility fee (APC 0092 
@ $979.92) 18.50 1.00 $1,499.47 $277.40
Total $839.46
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Table A2 Direct medical cost of mild-to-moderate PTS (Year 2+)
Resource use items Probability (%) Number of units Cost per unit Annual total cost
Ofﬁce visits $106.54
Physician visits (CPT 99213) 50.00 4.00 $47.23 $94.46
Wound care clinic visits/nurse visits 
(CPT 99211) 20.00 3.00 $20.14 $12.08
Vascular lab tests $104.40
Duplex ultrasound scan: physician fee 
(CPT 93970 @ $205.40) plus facility 
fee (APC 0267 @ $131.88) (every year 
for patients with moderate PTS; every 
3 years for patients with mild PTS) 50.00 0.58 $337.28 $98.02
Arterial Doppler: physician fee 
(CPT 93923 @ $119.36) plus facility fee 
(APC 0096 @ $99.88) (every year for 
patients with moderate PTS; every 
3 years for patients with mild PTS) 5.00 0.58 $219.24 $6.37
Medical supplies $130.00
Grade 2 elastic compression stockings 
(knee-high 30–40 mmHg from Jobst), two 
pairs every 6 months 50.00 4.00 $65.00 $130.00
Total $340.94
Table A3 Direct medical cost of severe PTS (open ulcer) (Year 1)
Resource use items Probability (%) Number of units Cost per unit Annual total cost
Annual comprehensive cost to heal 
ulcer (by size) $2711.95
Ulcer <5cm2 [24] 36.10 1.00 $1371.63 $495.16
Ulcer 5–20cm2 [24] 37.30 1.00 $2044.52 $762.61
Ulcer >20cm2 [24] 26.60 1.00 $5466.87 $1454.19
Medical supplies $202.48
Grade 2 elastic compression stockings 
(knee-high 30–40 mmHg from Jobst),
one pair during the last 6 months of 
the year (when ulcer is healed) 100.00 2.00 $65.00 $130.00
Pneumatic compressor (EO650 @ 
$515.22 using Medicare DMEPOS 
Fee Schedule 2000) and accessory 
(EO666 @ $98.80 Medicare DMEPOS 
Fee Schedule 2000)—when purchased 7.00 1.00 $614.02 $42.98
Pneumatic compressor (EO650 @ $84.76
using Medicare DMEPOS Fee Schedule 
2000) and accessory (EO666 @ $13.58 
Medicare DMEPOS Fee Schedule 
2000)—when leased 10.00 3.00 $98.34 $29.50
Medications $65.82
Steroid creams (for dermatitis): generic 
0.2% Westcort cream (hydrocortisone 
valerate,Apothecon), 60-g tube 10.00 1.00 $35.06 $3.51
Antibiotic (500 mg ciproﬂoxacin bid for 
10 days) 75.00 1.00 $83.09 $62.32
Vein ligation and stripping $181.73
Inpatient: hospital fee (DRG 119 
@ $5041.77) plus physician fees 
(CPT 37730 @ $519.55) and one 
physician visit per day for 4.9 days for 
subsequent inpatient management 
(CPT 99231 @ $35.88) 0.75 1.00 $5737.13 $43.03
Outpatient: physician fee (CPT 37730 
@ $519.55) plus facility fee 
(APC 0092 @ $979.92) 9.25 1.00 $1499.47 $138.70
SEPS procedure $102.58
Inpatient: hospital and operating room 
actual costs ($3959.33) plus physician 
fees (CPT 37760 @ $676.62) and one 
physician visit per day for 1.3 days for 
subsequent inpatient management 
(continued)
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Table A3 continued
Resource use items Probability (%) Number of units Cost per unit Annual total cost
(CPT 99231 @ $35.88) [27] 1.00 1.00 $4682.60 $46.83
Outpatient: physician fee (CPT 37760 
@ $676.62) plus facility fee (APC 0091 
@ $717.12) 4.00 1.00 $1393.74 $55.75
Other hospitalizations/surgeries $552.25
Additional hospitalization: hospital fee 
(DRG 271 @ $4061.05) plus physician 
fees (CPT 99223 @ $154.88) and one 
physician visit per day for 6.1 days for 
subsequent inpatient management 
(CPT 99232 @ $56.02) [24] 6.90 1.00 $4557.65 $314.48
Amputation: hospital fee (DRG 113 
@ $11,186.03) plus physician fees 
(CPT 27880 @ $844.68) and one 
physician visit per day for 12.6 days for 
subsequent inpatient management 
(CPT 99232 @ $56.02) [24] 0.40 1.00 $12736.56 $50.95
Skin graft: hospital fee (DRG 120 
@ $8256.00) plus physician fees 
(CPT 20926 @ $382.00) and one physician
visit per day for 8.2 subsequent days 2.00 1.00 $9097.36 $181.95
Debridement: physician fee (CPT 11042 
@ $72.86) plus facility fee (APC 0016 
@ $171.16) 2.00 1.00 $244.02 $4.88
Total $3816.81
Table A4 Direct medical cost of severe PTS (open recurrent ulcer) (Year 2+)
Resource use items Probability (%) Number of units Cost per unit Annual total cost
Annual comprehensive cost to 
heal ulcer (by size) $2711.95
Ulcer <5cm2 [24] 36.10 1.00 $1371.63 $495.16
Ulcer 5–20cm2 [24] 37.30 1.00 $2044.52 $762.61
Ulcer >20cm2 [24] 26.60 1.00 $5466.87 $1454.19
Medical supplies $202.48
Grade 2 elastic compression stockings
(knee-high 30–40 mmHg from Jobst),
one pair during the last 6 months of the 
year (when ulcer is healed) 100.00 2.00 $65.00 $130.00
Pneumatic compressor (EO650 
@ $515.22 using Medicare DMEPOS 
Fee Schedule 2000) and accessory 
(EO666 @ $98.80 Medicare DMEPOS 
Fee Schedule 2000)—when purchased 7.00 1.00 $614.02 $42.98
Pneumatic compressor (EO650 
@ $84.76 using Medicare DMEPOS 
Fee Schedule 2000) and accessory 
(EO666 @ $13.58 Medicare DMEPOS 
Fee Schedule 2000)—when leased 10.00 3.00 $98.34 $29.50
Steroid creams (for dermatitis):
generic 0.2% Westcort cream 
(hydrocortisone valerate,Apothecon),
60-g tube 10.00 1.00 $35.06 $3.51
Antibiotic (500 mg ciproﬂoxacin bid for 
10 days) 75.00 1.00 $83.09 $62.32
Other hospitalizations/surgeries $314.48
Additional hospitalization: hospital fee 
(DRG 271 @ $4061.05) plus physician 
fees (CPT 99223 @ $154.88) and one 
physician visit per day for 6.1 days for 
subsequent inpatient management 
(CPT 99232 @ $56.02) [24] 6.90 1.00 $4557.65 $314.48
Total $3294.73
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Table A5 Direct medical cost of severe PTS (healed ulcer) (Year 2+)
Resource use items Probability (%) Number of units Cost per unit Annual total cost
Ofﬁce visits $291.44
Physician visits (CPT 99214) 100.00 4.00 $72.86 $291.44
Vascular lab tests $381.13
Duplex ultrasound scan: physician fee 
(CPT 93970 @ $205.40) plus facility fee
(APC 0267 @ $131.88) 100.00 1.00 $337.28 $337.28
Arterial Doppler: physician fee 
(CPT 93923 @ $119.36) plus 
facility fee (APC 0096 @ $99.88) 20.00 1.00 $219.24 $43.85
Medical supplies $260.00
Grade 2 elastic compression stockings 
(knee-high 30–40 mmHg from Jobst),
two pairs every 6 months 100.00 4.00 $65.00 $260.00
Total $932.57
